- Home
- ASPI vs MYGN Comparison
ASPI vs MYGN Comparison
Compare ASPI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- MYGN
- Stock Information
- Founded
- ASPI 2021
- MYGN 1991
- Country
- ASPI United States
- MYGN United States
- Employees
- ASPI N/A
- MYGN N/A
- Industry
- ASPI Major Chemicals
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ASPI Industrials
- MYGN Health Care
- Exchange
- ASPI Nasdaq
- MYGN Nasdaq
- Market Cap
- ASPI 653.4M
- MYGN 625.5M
- IPO Year
- ASPI 2022
- MYGN 1995
- Fundamental
- Price
- ASPI $5.91
- MYGN $7.89
- Analyst Decision
- ASPI Strong Buy
- MYGN Hold
- Analyst Count
- ASPI 1
- MYGN 13
- Target Price
- ASPI $11.00
- MYGN $12.58
- AVG Volume (30 Days)
- ASPI 7.3M
- MYGN 1.2M
- Earning Date
- ASPI 11-19-2025
- MYGN 11-03-2025
- Dividend Yield
- ASPI N/A
- MYGN N/A
- EPS Growth
- ASPI N/A
- MYGN N/A
- EPS
- ASPI N/A
- MYGN N/A
- Revenue
- ASPI $8,383,354.00
- MYGN $825,300,000.00
- Revenue This Year
- ASPI $264.27
- MYGN $0.06
- Revenue Next Year
- ASPI $361.18
- MYGN $5.68
- P/E Ratio
- ASPI N/A
- MYGN N/A
- Revenue Growth
- ASPI 147.78
- MYGN 0.21
- 52 Week Low
- ASPI $3.65
- MYGN $3.76
- 52 Week High
- ASPI $14.49
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- ASPI 33.45
- MYGN 61.94
- Support Level
- ASPI $5.70
- MYGN $6.43
- Resistance Level
- ASPI $8.09
- MYGN $6.89
- Average True Range (ATR)
- ASPI 0.90
- MYGN 0.41
- MACD
- ASPI -0.24
- MYGN 0.15
- Stochastic Oscillator
- ASPI 10.78
- MYGN 91.18
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.